Correction to “A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis”

Abstract

Figure 6. (a) Establishment process of hepatic fibrosis model mice. (b) Imaging APN levels in mouse models of hepatic fibrosis. Control group: no treatment for 6 weeks. 3-week group: no treatment for the first 3 weeks, and subcutaneous injection of oil solution (CCl₄:olive oil = 1:4) with 20% CCl₄ by volume fraction at 5 mL/kg body weight every 3 days for 3 weeks. 6-week group of mice were stimulated with CCl₄ for 6 weeks consecutively in the same way as the 3-week group. Mice in the CCl₄ + bestatin group were stimulated with After 6 weeks of continuous stimulation with CCl₄, mice in the CCl₄ + bestatin group were pretreated with bestatin (100 μmol/L in saline) for 1 h prior to incubation of the probes. (c) Isolated organ fluorescence imaging (heart, liver, spleen, kidneys, and lungs). (d) Pathology of H&E in different test groups. (e) The images’ mean fluorescence intensity (b). (f) Body-weight changes. (****p < 0.0001.) Scale bar = 20 μm. This article has not yet been cited by other publications.